ASH Clinical News ACN_5.4s_March_supplement_web | Page 3

MARCH 2019 AMERICAN SOCIETY OF HEMATOLOGY HEADQUARTERS 2021 L Street NW, Suite 900 Washington, DC 20036 www.hematology.org Tel: [phone] EDITOR-IN-CHIEF Mikkael Sekeres, MD, MS Vice-Chair for Clinical Research Director, Leukemia Program Cleveland Clinic, Taussig Cancer Institute Cleveland, OH ASSOCIATE EDITORS Elizabeth Brém, MD UC Irvine Medical Center Orange, CA Beth Faiman, CNP, PhD Cleveland Clinic Cleveland, OH CONTENTS Alice Ma, MD University of North Carolina School of Medicine Chapel Hill, NC David Steensma, MD Dana-Farber Cancer Institute Boston, MA Keith Stewart, MBChB, MBA Mayo Clinic Scottsdale, AZ PUBLISHER American Medical Communications EDITORIAL MANAGING EDITORS Kristin Hubing, ASH Ariel Jones-DeMaio, AMC EDITORIAL COORDINATOR Laurie Adamson, ASH ART DIRECTOR Ari Mihos ASSISTANT ART DIRECTOR Charlene DePrizio DIGITAL PROJECTS MANAGER Chris Gedikli ADVERTISING ACCOUNT DIRECTORS Nick Luciano [email protected] NEWLY APPROVED DRUGS A review of the regulatory approvals for lymphoid malignancies from the last year, including the first biosimilar version of rituximab 10 IN THE LITERATURE Lenalidomide Maintenance Extends Survival Over Observation Alone in Newly Diagnosed Myeloma 11 A BCMA-Targeting Antibody Associated With Clinical Activity in Previously Treated Myeloma 12 Nivolumab Fails to Meet Endpoint in Relapsed/Refractory DLBCL 13 Ibrutinib Plus Nivolumab Appears Similar to Single-Agent Therapy in Early-Phase Trial 14 MEETING NEWS Updates in lymphoid malignancies from recent medical meetings 15 FEATURE Hodgkin Lymphoma: Beyond ABVD for Everyone 20 Gene Conselyea [email protected] Phil Soufleris [email protected] Recruitment advertising orders can be sent to: DIRECTOR, RECRUITMENT CLASSIFIEDS Lauren Morgan [email protected] ©2019 by the American Society of Hematology. All materials contained in this newsletter are protected by copyright laws and may not be used, reproduced, or otherwise exploited in any manner without the express prior written permission of ASH Clinical News. Any third-party materials communicated to ASH Clinical News become its copyrighted property and may be used, reproduced, or otherwise exploited by ASH Clinical News. All correspondence for the American Society of Hematology should be sent to: American Society of Hematology, 2021 L Street NW, Suite 900, Washington DC 20036. Neither the American Society of Hematology nor the publisher is responsible for statements made by any editor or con- tributor. Statements, editorials, or opinions expressed in ASH Clinical News magazine do not necessarily represent official policy of the American Society of Hematology unless so stated. No responsibility is assumed by the American Society of Hematology or the Publisher for any injury or damage to persons or property as a matter of product liability, negligence or otherwise or from any use or operation of any methods, products, instructions or ideas contained in the material herein.  Although all advertising material published in ASH Clinical News magazine is expected to conform to ethical (med- ical) standards, inclusion in this publication does not constitute a guarantee or endorsement by the American Society of Hematology or the Publisher of the quality or value of such product or of the claim made of it by its manufacturer. About the American Society of Hematology The American Society of Hematology (ASH) is the world’s largest professional society concerned with the causes and treatments of blood disorders. The mission of the Society is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. March 2019 1